IDBS, a global life sciences software company and Synthace, a pioneer software for automated biology experimentation and insight sharing, have entered a strategic partnership to provide IDBS Polar users with state-of-the-art data foundations for experimentation in high-throughput process development (HTPD).
Customers and regulators expect the highest level of data integrity to get the most out of data and ensure compliance.
IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform. Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.
Unlocking the power of advanced analytics to optimize biopharma development
Polar BioAnalysis enables CROs and biopharma to improve quality and reproducibility, reduce study cycle times and accelerate time-to-market.
Global life sciences software company IDBS announces the acquisition of biopharmaceutical manufacturing data management and analytics software developer Skyland Analytics, in a move that will create the first BioPharma Lifecycle Management (BPLM) offering that supports therapies from early development through commercial manufacturing.
Global life sciences software company IDBS announces the acquisition of biopharmaceutical manufacturing data management and analytics software developer Skyland Analytics, in a move that will create the first BioPharma Lifecycle Management (BPLM) offering that supports therapies from early development through commercial manufacturing. Skyland Analytics is best known for its Skyland PIMS™ software which seamlessly combines product, process, and patient data across the biopharma lifecycle and supply chain, providing insights that accelerate process understanding and ensure product quality.
When you factor in the unpredictability and complexity of therapies like biologics, the time impacts of poorly managed data are on the order of 6–18 months. Find out more on why legacy data management systems can’t support the directions…
As the Covid-19 pandemic puts a renewed focus on the time and cost of bringing new therapeutics and vaccines to market, this report explores why implementing a biopharma 4.0 approach is necessary for achieving higher flexibility, efficiency and robustness in…
What you need to know about the security, business continuity and customer responsibilities of our cloud platform